CardioCel® is bovine pericardium which is subjected to a novel tissue engineering process (ADAPT®) to reduce cytotoxicity and retard calcification while maintaining strength and elasticity. We present a case where CardioCel® showed rapid degeneration and calcification after repair of an aortic valve.
Get full access to this article
View all access options for this article.
References
1.
NordmeyerSMurinPSchulzA, et al. Results of aortic valve repair using decellularized bovine pericardium in congenital surgery. Eur J Cardiothorac Surg. 2018;54(6):986-992.
2.
IonescuMITandonAPMaryDA, et al. Heart valve replacement with the Ionescu-Shiley pericardial xenograft. J Thorac Cardiovasc Surg.1977;73(1):31-42.
3.
NeethlingWMStrangeGFirthL, et al. Evaluation of a tissue-engineered bovine pericardial patch in paediatric patients with congenital cardiac anomalies: initial experience with the ADAPT-treated CardioCel® (R) patch. Interact Cardiovasc Thorac Surg. 2013;17(4):698-702.
4.
PavyCMichielonGRobertusJL, et al. Initial 2-year results of CardioCel® patch implantation in children. Interact Cardiovasc Thorac Surg. 2018;26(3):448-453.
5.
MazzitelliDNobauerCRankinJS, et al. Complete aortic valve cusp replacement in the pediatric population using tissue-engineered bovine pericardium. Ann Thorac Surg.2015;100(5):1923-1925.
6.
ChiversSCPavyCVajaR, et al. The Ozaki procedure with CardioCel® patch for children and young adults with aortic valve disease: preliminary experience - a word of caution. World J Pediatr Congenit Heart Surg.2019;10(6):724-730.
